Dr. Katharine E. Spink, also known as Katy, Ph.D., has been a Consultant of Asterias Biotherapeutics, Inc. since January 19, 2018. Dr. Spink served as Chief Operating Officer and Executive Vice President of Asterias Biotherapeutics, Inc. from March 2013 to January 19, 2018 and from June 26, 2017 to January 19, 2018 respectively. Dr. Spink served as Vice President of Asterias Biotherapeutics, Inc. until September 05, 2015. Dr. Spink served as Senior Vice President of Alliance Management and Cell Therapy Product Development at Geron Corporation until November 2011. She served as a Senior Vice President of Operations for Cell Therapy Programs at Geron Corporation since February 2011. Dr. Spink served as a Vice President of Operations for Regenerative Medicine Programs at Geron Corporation from February 2009 to February 2011. From January 2008 to February 2009, Dr. Spink served as a Senior Director of Regenerative Medicine Program Operations at Geron Corporation. From January 2007 to January 2008, Dr. Spink served as Program Director of Cardiovascular Disease at Geron Corporation. Dr. Spink joined Geron in December 2003 and served various roles within Corporate Development group until January 2007. Prior to joining Geron, Dr. Spink was a management consultant at McKinsey & Company, advising clients in the biotechnology, pharmaceutical and medical device industries on matters relating to R&D strategy, business development and marketing. Dr. Spink graduated Magna Cum Laude and Phi Beta Kappa with a B.A. in Biochemistry from Rice University and received her Ph.D. in Cancer Biology from Stanford University.